Moderna’s mRNA respiratory syncytial virus (RSV) vaccine, mRESVIA, has received approval from the European Commission for adults aged 60 and older. This follows the positive opinion from the European Medicines Agency and comes after the FDA’s approval in May. Meanwhile, Moderna also secured approval for an updated formulation of its COVID-19 vaccine in Japan, targeting the Omicron subvariant JN.1. These approvals solidify Moderna’s position as a leading player in the mRNA vaccine space.